Misplaced Pages

Cetirizine/pseudoephedrine (Zyrtec-D) is an antihistamine and decongestant formulation. It is a fixed-dose combination drug containing 5 mg cetirizine hydrochloride and 120 mg pseudoephedrine hydrochloride for symptoms related to seasonal allergic rhinitis. Cetirizine/pseudoephedrine gained approval from the U.S. Food and Drug Administration in 2001 as a prescription drug and became over-the-counter (OTC) in 2007.

References

1. "ZYRTEC-D ALLERGY PLUS CONGESTION- cetirizine hydrochloride and pseudoephedrine hydrochloride tablet, film coated, extended release". DailyMed. 25 April 2022. Retrieved 28 September 2022.
2. Badorrek P, Dick M, Schauerte A, Hecker H, Murdoch R, Luettig B, et al. (February 2009). "A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis". International Journal of Clinical Pharmacology and Therapeutics. 47 (2). Dustri-Verlgag Dr. Karl Feistle: 71–77. doi:10.5414/cpp47071. PMID 19203562.
3. Grosclaude M, Mees K, Pinelli ME, Lucas M, Van de Venne H (June 1997). "Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis". Rhinology. 35 (2): 67–73. CiteSeerX 10.1.1.500.9540. PMID 9299654.
4. "FDA approves J&J's non-prescription Zyrtec-D". PharmaTimes. 12 November 2007. Retrieved 12 December 2022.

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Antihistamines
• Combination drugs
• Respiratory system drug stubs